Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.52 |
| ▸ | TTR | P02766 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5740018 | 0.94 | TTR (0.61) | ALDH1A1TDP1CYP3A4TSHRKMT2A | |
| SCHEMBL29682640 | 0.87 | ALDH1A1 (0.50) | ALDH1A1TDP1CYP3A4TSHRKMT2A | |
| SCHEMBL22698 | 0.87 | ALDH1A1 (0.50) | ALDH1A1TDP1CYP3A4TSHRKMT2A | |
| SCHEMBL3824914 | 0.87 | ALDH1A1 (0.63) | ALDH1A1TDP1CYP3A4TSHRKMT2A | |
| SCHEMBL2156946 | 0.87 | ALDH1A1 (0.63) | ALDH1A1TDP1CYP3A4TSHRKMT2A | |
| SCHEMBL30825381 | 0.85 | ALDH1A1 (0.62) | ALDH1A1TDP1CYP3A4TSHRKMT2A | |
| SCHEMBL4337680 | 0.85 | ALDH1A1 (0.62) | ALDH1A1TDP1CYP3A4TSHRKMT2A | |
| SCHEMBL176357 | 0.85 | TTR (0.68) | ALDH1A1TDP1CYP3A4TSHRKMT2A | |
| SCHEMBL13461422 | 0.84 | PDK1 (0.50) | ALDH1A1TDP1CYP3A4TSHRKMT2A | |
| SCHEMBL5518774 | 0.84 | ALDH1A1 (0.65) | ALDH1A1TDP1CYP3A4TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114621437-B | Compound for preparing photosensitive resin film, preparation method and application thereof | 吉林奥来德光电材料股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-107011266-B | Prodrug of benzimidazole derivative, preparation method and application thereof | 中国人民解放军第二军医大学 | 2023-04-14 | — | — | CN | disclosed |
| US-20220395500-A1 | SMALL MOLECULE ACTIVATORS OF INTERFERON REGULATORY FACTOR 3 AND METHODS OF USE THEREOF | NEURALEXO, INC. | 2022-12-15 | — | — | US | disclosed |
| CN-114621437-A | Compound for preparing photosensitive resin film, preparation method and application thereof | 吉林奥来德光电材料股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-111604021-B | Oxidation reaction system for preparing red-based KD and control method thereof | 舟山欧莱克新材料科技有限公司 | 2022-04-08 | — | — | CN | disclosed |
| WO-2021226129-A1 | SMALL MOLECULE ACTIVATORS OF INTERFERON REGULATORY FACTOR 3 AND METHODS OF USE THEREOF | NEURALEXO, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| CN-111604021-A | Oxidation reaction system for preparing red-based KD and control method thereof | 舟山欧莱克新材料科技有限公司 | 2020-09-01 | — | — | CN | disclosed |
| CN-111606910-A | Synthesis process of antitumor drug Sapanisiertib | 药璞(上海)医药科技有限公司 | 2020-09-01 | — | — | CN | disclosed |
| US-10130633-B2 | Compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-20 | — | — | US | disclosed |
| US-9688637-B2 | 3-amidobenzamides and uses thereof for increasing cellular levels of A3G and other A3 family members | NORTHWESTERN UNIVERSTIY (US) | 2017-06-27 | — | — | US | disclosed |
| US-4992360-A | Silver halide light-sensitive photographic material containing a novel yellow coupler | KONICA CORPORATION (JP) | 1991-02-12 | — | — | US | disclosed |
| EP-0267491-A2 | Silver halide light-sensitive photographic material containing a novel yellow coupler | KONICA CORPORATION (JP) | 1988-05-18 | — | — | EP | disclosed |
| US-4705861-A | AZO DYE CHEMICAL INTERMEDIATES | BAYER AKTIENGESELLSCHAFT (DE) | 1987-11-10 | — | — | US | disclosed |
| US-4695405-A | Process for quenching fluorescence, and new cationic or amphoteric aromatic nitro compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1987-09-22 | — | — | US | disclosed |
| EP-0163854-A2 | Process for the elimination of fluorescence and cationic or amphoteric aromatic nitro compounds | BAYER AG (DE) | 1985-12-11 | — | — | EP | disclosed |
| US-4125368-A | Metallized monoazo dyes | TOMS RIVER CHEMICAL CORP. (US) | 1978-11-14 | — | — | US | disclosed |
| US-4058515-A | Metallized phenyl-azo-naphthol compounds | TOMS RIVER CHEMICAL CORPORATION (US) | 1977-11-15 | — | — | US | disclosed |
| US-4052444-A | DIAZO COUPLERS FOR MONOAZO DYES | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-10-04 | — | — | US | disclosed |
| US-4051122-A | Disazo pigments containing tetracarboxylic acid ester groups | CIBA-GEIGY CORPORATION (US) | 1977-09-27 | — | — | US | disclosed |
| US-3971741-A | DISPERSION PIGMENTS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395500-A1 | SMALL MOLECULE ACTIVATORS OF INTERFERON REGULATORY FACTOR 3 AND METHODS OF USE THEREOF | IRF3, IRF2BP2, STAT1 | ALDH1A1 4853/4885TDP1 1011/4885CYP3A4 4733/4885 |
| US-10130633-B2 | Compounds | AADAC, NAT1, CBR3 | ALDH1A1 277/4885TDP1 4346/4885CYP3A4 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.